Abilify News and Research

RSS
Aripiprazole (marketed as Abilify, Abilify Discmelt) is an atypical antipsychotic medication approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.
The electronics industry sees money in your health

The electronics industry sees money in your health

With hospitalization losing favor, judges order outpatient mental health treatment

With hospitalization losing favor, judges order outpatient mental health treatment

FDA chief says he’s open to rethinking incentives on orphan drugs

FDA chief says he’s open to rethinking incentives on orphan drugs

Patients with rare diseases and congress square off over orphan drug tax credits

Patients with rare diseases and congress square off over orphan drug tax credits

Digital pills can help track opioid use patterns

Digital pills can help track opioid use patterns

FDA approves first digital pill with sensor - Abilify MyCite

FDA approves first digital pill with sensor - Abilify MyCite

FDA approves first drug with digital ingestion tracking system

FDA approves first drug with digital ingestion tracking system

House Republicans aim to yank tax credits for orphan drugs

House Republicans aim to yank tax credits for orphan drugs

FDA moves to guard against abuse of ‘orphan drug’ program

FDA moves to guard against abuse of ‘orphan drug’ program

UCLA-led study to evaluate treatment strategies for older adults with depression

UCLA-led study to evaluate treatment strategies for older adults with depression

EPFL scientists develop new method to cheaply produce chemical compounds

EPFL scientists develop new method to cheaply produce chemical compounds

Two-drug combination relieves depression in older adults

Two-drug combination relieves depression in older adults

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

First-ever comprehensive study of species origins of nature-derived drugs

First-ever comprehensive study of species origins of nature-derived drugs